Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23059633 | 0.91 | TSHR (0.44) | TSHRHPGDALDH1A1CYP3A4TP53 | |
| SCHEMBL22251732 | 0.88 | TSHR (0.43) | TSHRHPGDALDH1A1CYP3A4TP53 | |
| SCHEMBL21190228 | 0.81 | TSHR (0.32) | TSHR | |
| SCHEMBL26401138 | 0.76 | TSHR (0.33) | TSHRHPGDALDH1A1CYP3A4TP53 | |
| SCHEMBL26398013 | 0.75 | TSHR (0.39) | TSHRHPGDALDH1A1CYP3A4TP53 | |
| SCHEMBL21778998 | 0.73 | TSHR (0.46) | TSHRHPGDALDH1A1CYP3A4TP53 | |
| SCHEMBL23979736 | 0.72 | TSHR (0.37) | TSHRHPGDALDH1A1CYP3A4TP53 | |
| SCHEMBL12510864 | 0.72 | TSHR (0.46) | TSHRHPGDALDH1A1CYP3A4TP53 | |
| SCHEMBL22064599 | 0.71 | TSHR (0.39) | TSHRHPGDALDH1A1CYP3A4TP53 | |
| SCHEMBL23104919 | 0.71 | TSHR (0.44) | TSHRALDH1A1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10990011-B2 | Curable composition for imprinting, cured product, pattern forming method, and lithography method | FUJIFILM CORPORATION (JP) | 2021-04-27 | — | — | US | disclosed |
| US-20190163059-A1 | CURABLE COMPOSITION FOR IMPRINTING, CURED PRODUCT, PATTERN FORMING METHOD, AND LITHOGRAPHY METHOD | FUJIFILM CORPORATION (JP) | 2019-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10990011-B2 | Curable composition for imprinting, cured product, pattern forming method, and lithography method | DNMT3L, MMAB, DNMT1 | TSHR 4627/4885HPGD 4306/4885ALDH1A1 2533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.